SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Up 64.4% in February

SOPHiA GENETICS SA (NASDAQ:SOPH) was the target of a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 61,800 shares, a growth of 64.4% from the February 13th total of 37,600 shares. Based on an average daily trading volume, of 74,500 shares, the short-interest ratio is currently 0.8 days. Approximately 0.1% of the company’s shares are sold short.

Institutional Trading of SOPHiA GENETICS

Large investors have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. boosted its stake in SOPHiA GENETICS by 6.3% in the third quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company’s stock valued at $5,290,000 after acquiring an additional 86,764 shares during the last quarter. Green Alpha Advisors LLC lifted its stake in SOPHiA GENETICS by 119.3% in the fourth quarter. Green Alpha Advisors LLC now owns 47,216 shares of the company’s stock valued at $145,000 after purchasing an additional 25,686 shares during the last quarter. Silverberg Bernstein Capital Management LLC bought a new position in SOPHiA GENETICS during the fourth quarter valued at $70,000. Millennium Management LLC grew its holdings in SOPHiA GENETICS by 6.5% during the fourth quarter. Millennium Management LLC now owns 698,634 shares of the company’s stock valued at $2,180,000 after purchasing an additional 42,689 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in SOPHiA GENETICS by 23.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 21,619 shares of the company’s stock worth $68,000 after buying an additional 4,115 shares during the last quarter. Hedge funds and other institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Stock Performance

Shares of NASDAQ SOPH traded up $0.10 during midday trading on Friday, reaching $3.22. The company’s stock had a trading volume of 30,934 shares, compared to its average volume of 69,599. The stock has a market capitalization of $214.73 million, a P/E ratio of -2.95 and a beta of 1.01. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.80 and a quick ratio of 3.59. The firm has a 50 day moving average price of $3.58 and a 200-day moving average price of $3.54. SOPHiA GENETICS has a 12-month low of $2.70 and a 12-month high of $6.28.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.23) earnings per share for the quarter, hitting the consensus estimate of ($0.23). The business had revenue of $17.73 million for the quarter, compared to analysts’ expectations of $17.71 million. SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. As a group, equities analysts predict that SOPHiA GENETICS will post -0.96 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on SOPH shares. Craig Hallum assumed coverage on SOPHiA GENETICS in a research note on Wednesday, December 18th. They set a “buy” rating and a $11.00 target price for the company. BTIG Research set a $5.00 price objective on shares of SOPHiA GENETICS in a research note on Thursday, March 6th.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.